Bellerophon Therapeutics

Smith and speak to Mr. [email protected] On a per-share basis, the Warren, New Jersey-based company said it had a. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Reviews from Bellerophon Therapeutics employees about Bellerophon Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more. The man and woman exited a. By clicking this link, you'll be leaving the Bellerophon Therapeutics website and opening a site not sponsored by Bellerophon Therapeutics. Bellerophon Therapeutics serves customers in the State of New Jersey. 26% as of 1:24 PM on Monday, Feb 22. The company's product pipeline consists. 90 per share a year ago. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary. Free Online Library: Bellerophon Therapeutics awarded Belgium's health authority approval to begin Phase 2 trial of INOpulse in PH-COPD patients. Bellerophon Therapeutics LLC, a clinical-stage therapeutics company, focuses on the development of various products for the treatment of cardiopulmonary and cardiac diseases. “Bellerophon continues to advance multiple development programs for its INOpulse® inhaled nitric oxide therapy,” said Fabian Tenenbaum, Chief Executive Of. 05, Fidelity Earnings reports. com with copies to: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P. Bellerophon Therapeutics, Inc. About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of. With our deep scientific know-how and dedicated team, we are focused on making our vision a reality—creating life-changing cellular therapies for patients with cancer and autoimmune diseases. Free forex prices, toplists, indices and lots more. Bellerophon Therapeutics. bellerophon. Insider Buys Bellerophon Therapeutics Shares Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) gained by 5. -based company also gave underwriters a. Description: Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. de live verfolgen. Prior to joining New Mountain in 2005, Mr. Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 - Yahoo Finance nedeľa, 29 marec 2020 marketwatch. The inside of the arteries in the lungs may be damaged, narrowed, or obstructed. The company is focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. ボリンジャーバンドとは. Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19 Globe Newswire 11/23 08:30 ET. Our proprietary investigational drug, nantinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. See the details. Smith directly to learn how he can protect your rights. The stock has risen 20% in the …. is a clinical-stage therapeutics company. Smith and speak to Mr. Bellerophon Therapeutics Inc. Bellerophon Therapeutics's SIR currently stands at 3. 3/10/2020 8:37:14 AM Bellerophon Therapeutics Completes End-of-Phase 2 Meetings With FDA For INOpulse For PH-PF 2/19/2020 12:17:48 AM BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow. 30%: Market Cap: 63. Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19GlobeNewswire | 11/23/2020. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. We will …. (NASDAQ:BLPH) is not the least popular stock in this group but hedge fund interest is still below average. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. There are 9 older and 4 younger executives at Bellerophon Therapeutics Inc. insider trades are shown in the following chart. Anesthesia and Respiratory Devices Market - Global Opportunity Analysis and Industry Forecast, 2019–2027. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. 04%, Aktueller Kurs: 5. 1 Sea god who loved Scylla. 8% below the current share price. Common Stock (BLPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Bellerophon Therapeutics, Inc. Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) gap-opened higher Friday morning and were holding on to the gains during the trading session. Veränderung Vortag: 14. 54% while the S&P 500 is higher by 0. Bellerophon Therapeutics started at buy with $3 stock price target at Maxim Group MarketWatch. Moura worked at McKinsey & Company, where he helped to advise companies across various industries. , a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 - Yahoo Finance nedeľa, 29 marec 2020 marketwatch. (the "Company") issued a press release on November 23, 2020, to announce the results of the interim analysis of the Company's phase 3 COViNOX Study of INOpulse® for the treatment of COVID-19. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance. ( BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has initiated treatment in the Company's Phase 3 clinical study of INOpulse® inhaled nitric oxide (iNO) therapy for the treatment of COVID-19. He was "the greatest hero and slayer of monsters, alongside Cadmus and Perseus, before the days of Heracles", and his greatest feat was killing the Chimera, a monster that Homer depicted with a lion's head, a goat's body, and a serpent's. From PR Newswire. The post National Review Slams Trump's. Discovering targeted medicines. Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19 WARREN, N. Bellerophon Therapeutics. Do the numbers hold clues to what lies ahead for the. Bellerophon Therapeutics Inc (BLPH) stock has risen 6. de live verfolgen. Bellerophon Therapeutics, Inc. (“Bellerophon,” “we,” “us” and “our”) knows that you care how information about you is used and shared, and we appreciate your trust that we will do so carefully and sensibly. ボリンジャーバンドとは. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. short volume is shown in the following chart. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. This makes Bellerophon Therapeutics the world's 4589th most valuable company by market cap according to our data. Bellerophon Therapeutics Inc BLPH Morningstar Rating Rating as of Mar 12, 2021. The post National Review Slams Trump's. 7 million, which includes the full exercise of the underwriters' option to purchase additional shares. Bellerophon to Present at the H. A Form 4 filing filed with the SEC on Monday,. ABOUT US We are a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Employer Identification No. Smith and speak to Mr. The Investor Relations website contains information about Bellerophon Therapeutics, Inc. Bellerophon Therapeutics has reached its limit for free report views. Bellerophon Therapeutics NASDAQ Updated Mar 26, 2021 11:44 PM. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. in conjunction with this event. Website www. Key Topics Covered: CHAPTER 1: INTRODUCTION. Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Organization/Person Name. Bellerophon Therapeutics does not currently have any hardcopy reports on AnnualReports. He currently serves as a director of Bellerophon Therapeutics, Inc. Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock 5/21/20 WARREN, N. 48 from the previous closing price of $7. com website (the "Site"). Stay up to date with lastest Earnings Announcements for Bellerophon Therapeutics, Inc. Common Stock (BLPH) at Nasdaq. 00%, respectively, for the quarter ended September 2020. ("Bellerophon," "we," "us" and "our") knows that you care how information about you is used and shared, and we appreciate your trust that we will do so carefully and sensibly. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. Bellerophon Therapeutics Aktie (A2PZZR, US0787713009, 6L7A) Bellerophon Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. This information is presented for education purposes only. With our deep scientific know-how and dedicated team, we are focused on making our vision a reality—creating life-changing cellular therapies for patients with cancer and autoimmune diseases. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the. The company was founded in 2009 and is headquartered in Warren, NJ. Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment MarketWatch. Bellerophon Therapeutics, Inc. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary. 44% and -100. (BLPH) on Thursday reported a first-quarter loss of $795,000, after reporting a profit in the same period a year earlier. Bellerophon Therapeutics: Quartalsergebnisse zum jüngsten Jahresviertel (finanzen. (AP) _ Bellerophon Therapeutics Inc. 3 million, before deducting placement agent. 2020 was $10. Beam Therapeutics Announces Acquisition of Guide Therapeutics GuideTx’s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing CAMBRIDGE, Mass. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent. Organization/Person Name. Bellerophon Therapeutics Reports Q3 Loss, Lags Revenue Estimates Zacks via Yahoo Finance · 5 months ago. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary. If you acquired securities in Bellerophon Therapeutics, Inc. Our calculations showed that top 10 most popular stocks. The Company is currently developing multiple product candidates under its INOpulse® program, a. Bellerophon is developing inhaled nitric oxide therapy for pulmonary diseases and COVID-19. Bellerophon Therapeutics does not currently have any hardcopy reports on AnnualReports. Employer Identification No. Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. Bellerophon Therapeutics Inc. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and. In this SNNLive On-Location, our host spoke with Jonathan Peacock, Chairman and CEO of Bellerophon Therapeutics, Inc. 2020 was $57. Underwriting Agreement by and between Bellerophon Therapeutics, Inc. BELLEROPHON THERAPEUTICS. Bellerophon is developing inhaled nitric oxide therapy for pulmonary diseases and COVID-19. US0787713009. Bellerophon Therapeutics, Inc. Diabetic Nephropathy Market Key-Players & Forecast Research Report 2028 | Novartis AG, Eli Lilly, Bayer AG – The Bisouv Network The Bisouv Network Novartis AG, Eli Lilly, Bayer AG – The Bisouv Network. Smith and speak to Mr. You are also invited to Sign Up and join the Groups and Activity chats. MarketQuest. (the "Company") and H. Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease Globe Newswire 12/01 08:30 ET Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. The inhaled nitric oxide market provides extensive competitive analysis and profiles of Key market Players, such as Air Liquide S. 31: Insider Own: 7. (Nasdaq: BEAM), a biotechnology company developing. Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development. Parsley most recently served as Acting Chief Medical Officer for Respira Therapeutics, in the development of inhaled vardenafil powder for symptomatic use in pulmonary arterial hypertension (PAH). Get the most out. 65%, for an annualized return of -40. Report this profile Experience Vice President, Engineering and Manufacturing Bellerophon Therapeutics Jan 2015 - Present 6 years 2 months. Bellerophon Therapeutics Company Profile. 2021 in der Finanzkonferenz die Quartalszahlen zum jüngsten Jahresviertel – Abschlussdatum 31. Shares of Bellerophon Therapeutics have gained just 10% over the past year- recently the company lost around two-thirds of its value when the phase 3 INOvation-1 study in PAH failed to achieve its. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent Data. 7 million, or $3. Key Topics Covered: CHAPTER 1: INTRODUCTION. Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2. Our lead program is in Phase 2 clinical testing for the treatment of pulmonary arterial hypertension (PAH). Bellerophon Therapeutics shares have more than doubled since the beginning of the year. Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research note issued to investors on Wednesday, Zacks. Bellerophon Therapeutics (NSDQ:BLPH) last week closed an underwritten public offering of 10,000,000 shares of common stock at 70¢ apiece. 44% and -100. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and. Bellerophon is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be—in the lung and lung periphery, instead of in the. When an investor makes a short sale, they do so with the belief that a security will decline in price. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. (BLPH) on Thursday reported a loss of $8 million in its fourth quarter. (BLPH) "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise". The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension. Bellerophon Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted zero revenues for the quarter ended September 2020, missing the Zacks Consensus Estimate by. Bellerophon Therapeutics, Inc. Bellerophon Therapeutics LLC, a clinical-stage therapeutics company, focuses on the development of various products for the treatment of cardiopulmonary and cardiac diseases. Bellerophon Therapeutics (BLPH) came out with a quarterly loss of $0. Traders may explore shorting the stock or put options. com website (the "Site"). The company's product pipeline consists. Their average twelve-month price target is $26. BLPH stock traded up $0. bellerophon. 7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares, Stocks: BLPH, release date:May 22, 2020. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. Tuesday, September 05, 2017. Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) gained by 5. He currently serves as a director of Bellerophon Therapeutics, Inc. Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 Attention: Fabian Tenenbaum, Chief Executive Officer Email: Fabian. BLPH: Bellerophon Therapeutics, Inc. Email Address. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac. Die aktuell deutlich korrigierende Aktie wird damit wieder zu einem heißen Kauftipp. If shares price at the midpoint of that range, the company will raise $60 million and garner a valuation of nearly $179 million. (Nasdaq: BLPH) (“Bellerophon. analyst estimates, including BLPH earnings per share estimates and analyst recommendations. 44% and -100. Therefore, Bellerophon Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. stock and Biotechnology market discussion, news, and analysis from Canada's largest community of active investors. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. 63%: Shs Outstand: 9. (NASDAQ: BLPH) from February 13, 2015 through present you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. The acute intra-patient,. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. He currently serves as a director of Bellerophon Therapeutics, Inc. View today's stock price, news and analysis for Bellerophon Therapeutics Inc. Eureka Therapeutics, a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system. Cash and cash equivalents of $47. 666 Third Avenue New York, New York 10017 Facsimile: 212-983-3115. Bellerophon Therapeutics's SIR currently stands at 3. 184 Liberty Corner Road Suite 302 Warren, NJ 07059 United States. Bellerophon Therapeutics (BLPH) stock price, charts, trades & the US's most popular discussion forums. 4% from the previous closing price. Bellerophon Therapeutics: A Promising Solution To America's Ventilator Shortage During The COVID-19 Pandemic Apr. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary. Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) gap-opened higher Friday morning and were holding on to the gains during the trading session. 's focus is on the development of its nitric oxide therapy for patients with pulmonary hypertension using its proprietary pulsatile nitric oxide delivery platform. (the "Company") and H. From PR Newswire. Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary. Get reviews, hours, directions, coupons and more for Bellerophon Therapeutics at 53 Frontage Rd, Hampton, NJ 08827. 07, 2020 12:09 PM ET Bellerophon Therapeutics, Inc. News Corp is a network of leading companies in the worlds of diversified media, news. Key Topics Covered: CHAPTER 1: INTRODUCTION. Bellerophon Therapeutics Inc. bellerophon. 24—Detroit police have released surveillance images of two people wanted in connection with a shooting this month on the city's west side that left a man wounded. Semler Scientific, Inc. You are also invited to Sign Up and join the Groups and Activity chats. Bellerophon Therapeutics (NASDAQ:BLPH) announced its quarterly earnings data on Wednesday. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. Financial Statements and Exhibits. On a per-share basis, the Warren, New Jersey-based company said it had a loss of 84 cents. Bellerophon Therapeutics, Inc. At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. Bellerophon Therapeutics Inc BLPH Vitals. is an emerging medical risk-assessment company whose diagnostic and testing products and services help to guide patient care and close the gap between cost of care and compensation for care. Respira is a clinical-stage inhaled therapeutics company developing next-generation pulmonary targeted therapeutics to address significant unmet patient needs in cardio-pulmonary diseases. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Find out the direct holders, institutional holders and mutual fund holders for Bellerophon Therapeutics, Inc. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and. About Bellerophon. View today's stock price, news and analysis for Bellerophon Therapeutics Inc. 7 million, or $3. Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Bellerophon Therapeutics Inc. From PR Newswire. 666 Third Avenue New York, New York 10017 Facsimile: 212-983-3115. 8-million milestone payment from the. Bellerophon Therapeutics | 883 Follower auf LinkedIn Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website. Manage Account. 98) earnings per share for the current fiscal quarter, according to Zacks Investment Research. GET THE NEWSLETTER. is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary. Bellerophon Therapeutics LLC is a biotherapeutics company. 7% upside from current levels. The man and woman exited a. The transaction moved the executive's stake in Bellerophon Therapeutics Inc. Bellerophon Therapeutics (BLPH): FY GAAP EPS of -$3. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. INOpulse is a nitric oxide delivery system under development by Bellerophon Therapeutics. 00%, respectively, for the quarter ended September 2020. Bellerophon Therapeutics EPS beats by $0. Bellerophon Therapeutics, Inc. Traders may explore shorting the stock or put options. Founded 2007. Bellerophon Therapeutics (BLPH) came out with a quarterly loss of $0. 4% from the previous closing price. Bellerophon Therapeutics Announces Closing of $43. Employer Identification No. short volume is shown in the following chart. Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes. Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 - Yahoo Finance Sunday, 29 March 2020 marketwatch. 00 per share (the “Offerings”). com reports. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance. 7% upside from current levels. Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease. Bellerophon Therapeutics (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research note issued to investors on Tuesday, Zacks. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in. -based company also gave underwriters a. 21 Nov 16. q2 earnings per share estimate $-0. Bellerophon Therapeutics Inc BLPH financial information, fundamentals, key ratios, market capitalization, shares outstanding, float, and short interest. 79% while BLPH has gained 5. The company engages in two programs including INOpulse and BCM. (NASDAQ:BLPH) is not the least popular stock in this group but hedge fund interest is still below average. Bellerophon Therapeutics, Inc. Traders may consider selling the stock, shorting the stock, or exploring put options. The offering is expected to close on or about November 29, 2016. Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. Bellerophon Therapeutics Inc BLPH Morningstar Rating Rating as of Mar 12, 2021. DUBLIN—Can high-dose inhaled nitric oxide (NO) make a meaningful contribution to patients with COVID-19 infection? The FDA was sufficiently persuaded by the data presented by Bellerophon Therapeutics Inc. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth. 666 Third Avenue New York, New York 10017 Facsimile: 212-983-3115. Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. 84 per share versus the Zacks. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Company’s inhibitor of PI3k-delta and CK1-epsilon, in patients with relapsed or refractory indolent. The Company develops medical devices and drugs for the healtchcare industry, and primarily for cardiac related diseases. (US:BLPH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. US0787713009. Recent News & Activity. (BLPH) on Wednesday reported a loss of $3. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second. - SEC Filings - Registrant - CIK 1600132 - SEC. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial results for the second. 24, 2019 at 7:31 a. The company's product pipeline consists. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary. The company's product pipeline consists of. Warren, New Jersey Company Officer and member of. The company engages in two programs including INOpulse and BCM. 44% and -100. com reports. (BLPH) on Thursday reported a loss of $8 million in its fourth quarter. Free forex prices, toplists, indices and lots more. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. Bellerophon Therapeutics Inc is a biotherapeutics company. 4% from the previous closing price. About Bellerophon Therapeutics, Inc. Market Summary > Current Price The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical. Find Our February Issue Online and on Newsstands Now. With our deep scientific know-how and dedicated team, we are focused on making our vision a reality—creating life-changing cellular therapies for patients with cancer and autoimmune diseases. (“Bellerophon,” “we,” “us” and “our”) knows that you care how information about you is used and shared, and we appreciate your trust that we will do so carefully and sensibly. (10) | Advisory Agreements (1) Recent Contracts Advisory Agreement, by and between Bellerophon Therapeutics, Inc. Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. Prior to joining New Mountain in 2005, Mr. Bellerophon Therapeutics started at buy with $3 stock price target at Maxim Group Jan. Bellerophon Therapeutics, Inc. Whalewisdom has at least 1 13G filings, and 111 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2017-10-11. In other words for every 100,000 Bellerophon. Its product pipeline include PH-ILD, PH-COPD, and PH-Sarc. 06 this would imply there is a potential upside of 235. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Free forex prices, toplists, indices and lots more. Bellerophon Therapeutics Company Profile. Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. Bellerophon Therapeutics's operating liabilities for the quarter that ended in Dec. Its product candidat. 40 on volume of 433,287 shares. 21 , Thomas Heydrich DAX mit dem Ausbruch. Therefore, Bellerophon Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. Bellerophon Therapeutics, Inc. com is not responsible for any comments, advice, or annotations presented on this page. Shares of Bellerophon Therapeutics have gained just 10% over the past year- recently the company lost around two-thirds of its value when the phase 3 INOvation-1 study in PAH failed to achieve its. Bellerophon Therapeutics. Comparison of Jazz Pharmaceuticals plc (JAZZ) and Bellerophon Therapeutics Inc. 12/17/2019. 2020 was $57. 2/18/2020 10:33:43 AM Stock Alert: Bellerophon Therapeutics Soars 95%. Digital Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2019–2027. Bellerophon Therapeutics (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday, Zacks. Traders may consider selling the stock, shorting the stock, or exploring put options. 17 Seeking Alpha - 3/11/2021 9:18:45 AM: Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2021 8:36:24 AM Current Report Filing (8-k) Edgar (US Regulatory) - 1/11/2021 8:02:23 AM. Bellerophon Therapeutics Inc. This is a Bearish indicator signaling BLPH's price could decline from here. * BELLEROPHON THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED WITH INOPULSE® INHALED NITRIC OXIDE THERAPY FOR COVID-19 Source text for Eikon: Further company coverage:. This is the Bellerophon Therapeutics company profile. Bellerophon Therapeutics LLC is a clinical-stage therapeutics company developing products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Redx is a biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease. 's focus is on the development of its nitric oxide therapy for patients with pulmonary hypertension using its proprietary pulsatile nitric oxide delivery platform. Bellerophon Therapeutics is based out of Warren. 54 from the previous closing price of $8. 7% upside from current levels. BLPH is lower by -$1. Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M. Bellerophon Therapeutics has spent $140,000 lobbying in 2020, so far. , March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BEAM), a biotechnology company developing. Join The #1 Trader Newsletter. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. Warren, New Jersey-based Bellerophon said top-line results from the PHPF-002 study showed statistically and clinically significant improvements in hemodynamic parameters. 7 million, or $3. Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. 8 million in its second quarter. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics NASDAQ Updated Mar 24, 2021 11:54 PM 15. Get the latest up-to-the minute news on Bellerophon Therapeutics from ADVFN 11/03/2021 22:19:53 Cookie Policy +44 (0) 203 8794 460 Free Membership Login Monitor. Bellerophon Therapeutics Warren, New Jersey headquartered Bellerophon Therapeutics Inc. The company's product pipeline consists. BELLEROPHON THERAPEUTICS AKTIE und aktueller Aktienkurs. 2020 was $57. Ranked in Earnings Gainer and 1 other category Data delayed 15 minutes. 44% and -100. Developing a Fine Dining experience Fine Dining experience Fine Dining experience Voltron Therapeutics, Inc. The Schedule 13D indicates that the investor holds (or held. Shares of Bellerophon Therapeutics have gained just 10% over the past year- recently the company lost around two-thirds of its value when the phase 3 INOvation-1 study in PAH failed to achieve its. 00%, respectively, for the quarter ended September 2020. GET THE NEWSLETTER. , a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. 3/10/2020 8:37:14 AM Bellerophon Therapeutics Completes End-of-Phase 2 Meetings With FDA For INOpulse For PH-PF 2/19/2020 12:17:48 AM BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow. com website (the "Site"). Bellerophon Therapeutics. Our proprietary investigational drug, nantinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Our strategy is to discover, develop and commercialize safe and effective novel molecules that address and overcome mechanisms of antibiotic resistance in specific bacterial pathogens where the medical need is greatest. Get reviews, hours, directions, coupons and more for Bellerophon Therapeutics at 53 Frontage Rd, Hampton, NJ 08827. de live verfolgen. Respira is a clinical-stage inhaled therapeutics company developing next-generation pulmonary targeted therapeutics to address significant unmet patient needs in cardio-pulmonary diseases. At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. Bellerophon Therapeutics LLC is a biotherapeutics company. BLPH / Bellerophon Therapeutics, Inc. Bellerophon Therapeutics vs. BLPH: Bellerophon Therapeutics, Inc. 7 million, or $3. Bellerophon Therapeutics (NASDAQ: BLPH) is a clinical-stage biotherapeutics company. Number of Articles 3. Bellerophon Therapeutics 's earnings in 2021 is -$24,728,000. Bellerophon Therapeutics, Inc. ROMEG Therapeutics Secures Two Additional U. 2020 – vorgestellt. Bellerophon Therapeutics Inc. Bellerophon Therapeutics hat am 11. See the details. Free forex prices, toplists, indices and lots more. a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology. 2020 was -0. Bellerophon Therapeutics shares have fallen 1% since the beginning of the year. 84 per share versus the Zacks Consensus Estimate of a loss of $0. Wainwright & Co. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. Umsatz, Gewinn, KGV. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and. Celldex Therapeutics, Inc. Bellerophon Therapeutics (BLPH ) Notes: (1) As of September 30, 2019 per Quarterly Report on Form 10-Q filed November 6, 2019 and adjusted to reflect the reverse stock split that went into effect on February 7, 2020. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Bellerophon Therapeutics (BLPH) Reports Q3 Loss, Lags Revenue Estimates. 45 with a total trading volume of 275,765 shares. Bellerophon Therapeutics | 在领英上有 901 位关注者。Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Registered Shares DL -,01. Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis. Bellerophon Therapeutics LLC, (NASDAQ:BLPH)成立于2009年,总部在新泽西州汉普顿,2014年更名为Bellerophon Therape. We will …. Free Online Library: Bellerophon Therapeutics awarded Belgium's health authority approval to begin Phase 2 trial of INOpulse in PH-COPD patients. 21/03/2021 06:00:32 1-888-992-3836 Free. Technology Respira AOS™ Dry-Powder Inhaler Technology. ボリンジャーバンドとは. Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering, Stocks: BLPH, release date:May 19, 2020. Number of Articles 3. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes. Bellerophon's lead development candidate is INOpulse, a drug/. View the latest Bellerophon Therapeutics Inc. Developing Reliable Solutions for Antibacterial Resistance. Brokerages expect Bellerophon Therapeutics, Inc. 4% from the previous closing price. This policy may change as safety and efficacy are better demonstrated. (NASDAQ:BLPH) The FinReviewer Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Bellerophon Therapeutics Inc. A Form 4 filing filed with the SEC on Monday, September 14 showed that Fares Wassim bought 4,000 shares at an average price of $10. Therefore, Bellerophon Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. Bellerophon Therapeutics. Bellerophon Therapeutics, Inc. Moore is a Board member of the Board of Advisors and the Board of Directors of the Global Virus Network at the Institute of Human Virology (IHV), University of Maryland Medical Center, According to the National Science Foundation, UMB’s budget for research and development in 2019 was $1. Bellerophon Therapeutics Company Profile. BELLEROPHON THERAPEUTICS Attributes, charts, historical data, comparisons and more at Zacks Advisor Tools. Insiders are officers, directors, or significant investors in a company. The biotechnology company reported ($0. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. View BLPH historial stock data and compare to other stocks and exchanges. Uncover why Bellerophon Therapeutics is the best company for you. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company engages in the. Currently, the analyst consensus on Bellerophon is a Moderate Buy with an average price target of $3, a 376. 06 this would imply there is a potential upside of 235. Jonathan Gottesmann-September 28, 2015. Bellerophon Therapeutics's "short interest ratio" (SIR) is the quantity of Bellerophon Therapeutics shares currently shorted divided by the average quantity of Bellerophon Therapeutics shares traded daily (recently around 75156. Celldex Therapeutics, Inc. Whalewisdom has at least 1 13G filings, and 111 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2017-10-11. is currently unavailable. For the year, the company reported that its loss widened to $24. Bellerophon Therapeutics Inc(BLPH)の株価が、天井か底値か中立かを毎日判定します。数種類のテクニカル指標を組み合わせて天井と底値を判定します。. 33, changing hands for $13. 8-million milestone payment from the. Earnings for Bellerophon Therapeutics Inc. Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products for the treatment of cardiopulmonary diseases. Bellerophon is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Bellerophon Therapeutics LLC, (NASDAQ:BLPH)成立于2009年,总部在新泽西州汉普顿,2014年更名为Bellerophon Therape. This letter agreement (this “Agreement”) constitutes the agreement between Bellerophon Therapeutics, Inc. (AP) _ Bellerophon Therapeutics Inc. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and. The high price target for BLPH is $35. Bellerophon Therapeutics. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. The biotechnology company reported ($0. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical. Bellerophon Therapeutics LLC, is a clinical-stage biotherapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. Bellerophon Therapeutics, Inc. If you are looking for stocks with good return, Bellerophon Therapeutics Inc can be a profitable investment option. Our lead program is in Phase 2 clinical testing for the treatment of pulmonary arterial hypertension (PAH). Bellerophon Therapeutics LLC is based in Hampton, New Jersey. Bellerophon Therapeutics - What is pulmonary hypertension? What is pulmonary hypertension? Pulmonary hypertension is a disease that does not have a cure. 64M, as of Mar 13, 2021. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059. ("Bellerophon," "we," "us" and "our") knows that you care how information about you is used and shared, and we appreciate your trust that we will do so carefully and sensibly. About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of. Digital Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2019–2027. When an investor makes a short sale, they do so with the belief that a security will decline in price. 4% above the current share price. At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. is improving cell mediated responses to combat infectious diseases, such as COVID-19 and specific forms of cancers, using the advanced and proprietary VaxCelerate™ Self-Assembling Vaccine Design developed by specialists at the Massachusetts General Hospital (MGH) and the. found using ticker (BLPH) now have 3 analysts covering the stock with the consensus suggesting a rating of 'Buy'. It develops. biz offers a detailed research study on Global Nitric Oxide Therapy System Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which is a professional detailing of the important elements that drive the market growth rate and revenue statistics. Traders may explore shorting the stock or put options. 78 on volume of 399,959 shares. 1-908-574-4770. Parsley most recently served as Acting Chief Medical Officer for Respira Therapeutics, in the development of inhaled vardenafil powder for symptomatic use in pulmonary arterial hypertension (PAH). Shares of micro-cap biotherapeutics company Bellerophon Therapeutics Inc (NASDAQ: BLPH) gap-opened higher Friday morning and were holding on to the gains during the trading session. Real-time exchange rate quote of Bellerophon Therapeutics, Inc. Bellerophon Therapeutics Inc. About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines. The Warren, N. BELLEROPHON THERAPEUTICS Income Statement, Balance Sheet and Statement of Cash Flows. IN WITNESS WHEREOF, Bellerophon Therapeutics, Inc. Find out the direct holders, institutional holders and mutual fund holders for Bellerophon Therapeutics, Inc. Technology Respira AOS™ Dry-Powder Inhaler Technology. Salary ranges can vary widely depending on many important factors, including education, certifications, additional skills, the. 08:34 AM ET. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. , a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Website of Respira Therapeutics, Albuquerque, New Mexico. Respira is a clinical-stage inhaled therapeutics company developing next-generation pulmonary targeted therapeutics to address significant unmet patient needs in cardio-pulmonary diseases. and Jefferies LLC, dated May 18, 2020 (Filed With SEC on May 20, 2020) Underwriting Agreement, dated January 23, 2019, by and between Bellerophon Therapeutics, Inc. Wainwright & Co (Filed With SEC on January 23, 2019). Of this total $425,492 was received as a salary, $372,000 was received as a bonus, $585,704 was received in stock options, $0 was awarded as stock and $16,800 came from other types of compensation. Bellerophon Therapeutics, Inc. Bellerophon Therapeutics Company Profile. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the. BELLEROPHON THERAPEUTICS Technical Chart, charts, historical data, comparisons and more at Zacks Advisor Tools. 6MPress Release. The following slide deck was published by Bellerophon Therapeutics, Inc. The Company develops molecules deployed delivery systems to treat cardiopulmonary diseases. Bellerophon Therapeutics Inc (BLPH) Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products for the treatment of cardiopulmonary diseases. Digital Therapeutics Market - Global Opportunity Analysis and Industry Forecast, 2019–2027. Discovering targeted medicines. View BLPH historial stock data and compare to other stocks and exchanges. Parsley most recently served as Acting Chief Medical Officer for Respira Therapeutics, in the development of inhaled vardenafil powder for symptomatic use in pulmonary arterial hypertension (PAH). This indicator may be signaling that BLPH's price has further to drop, since it fell below its price logged 14 days ago. Bellerophon Therapeutics's SIR currently stands at 3. According to Zacks, "Bellerophon Therapeutics LLC is a biotherapeutics company. 6MPress Release. Description: Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in. Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 - Yahoo Finance Sunday, 29 March 2020 marketwatch. This notice describes our privacy policy for the www. About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of. Their average twelve-month price target is $26. Bellerophon Therapeutics Inc. Bellerophon Therapeutics (BLPH) Initiation Report LifeSci Investment Abstract Bellerophon Therapeutics (NasdaqGM: BLPH) is a clinical-stage biotherapeutics company focused on the development of inhaled nitric oxide (NO) therapy for patients with cardiopulmonary diseases. Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. 20/03/2021 08:14:14 1-888-992-3836 Free. Currently, the analyst consensus on Bellerophon is a Moderate Buy with an average price target of $3, a 376. Bellerophon Therapeutics EPS beats by $0. Bellerophon Therapeutics, Inc. Dabei wurde ein Verlust je Aktie. BELLEROPHON THERAPEUTICS News, charts, historical data, comparisons and more at Zacks Advisor Tools. is a clinical-stage therapeutics company. Bellerophon Therapeutics, Inc. Bellerophon Therapeutics's SIR currently stands at 3. Its products. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs. 90 per share a year ago. 17 per share. About Bellerophon. The man and woman exited a. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus. Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics. Bellerophon Therapeutics Company Profile. (Nasdaq: BLPH) (“Bellerophon. Bellerophon Therapeutics (BLPH) delivered earnings and revenue surprises of -2.